Skip to main content
bioXXmed AG logo

bioXXmed AG — Investor Relations & Filings

Ticker · T5O ISIN · DE000A4BGGE4 LEI · 8945005J8KVO36IW6P49 F Financial and insurance activities
Open in API
Filings indexed 5 across all filing types
Latest filing 2025-10-10 Annual Report
Country DE Germany
Listing F T5O

About bioXXmed AG

https://bioxxmed.ag/en/

bioXXmed AG is an investment and holding company focused on the biotechnology and medical technology sectors. Functioning as an active portfolio manager, it provides equity financing and development expertise to innovative companies. The company's strategy targets enterprises with patented, application-oriented technologies that address clinical indications with high unmet medical needs. A primary therapeutic focus is dermatology, with a specific emphasis on advanced wound care for chronic wounds, such as those associated with diabetes, and novel technologies in regenerative medicine. bioXXmed AG supports the development of new medical products and therapies, including small molecules and biologics, for the diagnosis, alleviation, or cure of diseases. The company was formerly known as CytoTools AG.

Recent filings

Filing Released Lang Actions
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 100% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for the fiscal year 2024, including a management report (Lagebericht), balance sheet (Bilanz), and profit and loss statement (Gewinn- und Verlustrechnung). It is a comprehensive financial report for the full fiscal year, not an announcement or a summary. Therefore, it is classified as an Annual Report (10-K). FY 2024
2025-10-10 German
bioXXmed AG: Verbindliches Angebot fur die Tochtergesellschaft Rancoderm GmbH aus dem M&A-Prozess angenommen; Kapitalmanahme zur Sicherstellung der Liquiditat beabsichtigt
M&A Activity Classification · 100% confidence The document is an ad-hoc announcement (insider information) regarding two primary events: the acceptance of a binding offer for the sale of a subsidiary (Rancoderm GmbH) and the announcement of a capital measure (issuance of a convertible bond). While it touches on M&A activity (TAR) and capital changes (SHA), the document is a formal regulatory disclosure of material information (Ad-hoc/Insider information) under EU Market Abuse Regulation. Given the dual nature of the announcement and its primary function as a regulatory disclosure, 'RNS' (Regulatory Filings) is the most appropriate classification for this type of corporate news release.
2025-08-28 German
bioXXmed AG informiert uber die Verzogerung der Veroffentlichung des gepruften Jahresabschlusses 2024
Report Publication Announcement Classification · 99% confidence The document is a short corporate news release (3387 characters) from bioXXmed AG, dated June 27, 2025. The headline and content explicitly state that the company is informing the public about a DELAY in the publication of its audited annual financial statements for 2024, pushing the expected release date to July 31, 2025. This is not the Annual Report (10-K) itself, nor is it the Audit Report (AR). It is an announcement regarding the timing of a report's release. According to Rule 2, if a document is short and announces the publication/timing of a report, it should be classified as a Report Publication Announcement (RPA).
2025-06-27 German
bioXXmed AG beschliet Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated February 21, 2025, disclosing that bioXXmed AG decided to issue a convertible bond (Wandelschuldverschreibung) while excluding pre-emptive subscription rights. This action directly relates to the company's financing activities and capital structure changes (issuing debt convertible into equity). This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is an announcement, the core subject matter is the financing event itself, not just the announcement of a report, making CAP more specific than RPA or RNS.
2025-02-21 German
Annual Report 2023
Annual Report Classification · 98% confidence The document contains a detailed 'Inhaltsverzeichnis' (Table of Contents) listing sections such as 'Brief an die Aktionäre' (Letter to Shareholders), 'Bericht Aufsichtsrat' (Supervisory Board Report), 'Lagebericht' (Management Report), 'Bilanz und GuV' (Balance Sheet and P&L), and 'Anhang' (Notes). This structure, combined with the comprehensive financial review for the fiscal year 2023 ('Kennzahlen 2023'), the discussion of the annual audit ('Der Prüfungsbericht ist den Aufsichtsratsmitgliedern rechtzeitig vor der Bilanzsi...'), and the overall scope, strongly indicates this is the company's official Annual Report, which corresponds to the US SEC filing type 10-K, even though this is a German filing. The length (80,205 characters) also supports it being a full annual report rather than a brief announcement. FY 2023
2024-06-27 German

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.